Evaxion A/S (EVAX) Expected to Announce Earnings on Wednesday

Evaxion A/S (NASDAQ:EVAX) is expected to be announcing its Q2 2025 earnings results before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.50) per share for the quarter.

Evaxion A/S (NASDAQ:EVAX) last released its quarterly earnings data on Tuesday, May 27th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.36. Evaxion A/S had a negative net margin of 316.03% and a negative return on equity of 532.72%. On average, analysts expect Evaxion A/S to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Evaxion A/S Trading Down 2.1%

Evaxion A/S stock opened at $2.77 on Tuesday. The stock has a market cap of $3.88 million, a P/E ratio of -2.39 and a beta of 0.13. The company has a 50-day moving average price of $2.63 and a 200 day moving average price of $2.21. Evaxion A/S has a 12-month low of $1.20 and a 12-month high of $17.75.

Analysts Set New Price Targets

Separately, Wall Street Zen upgraded shares of Evaxion A/S to a “hold” rating in a report on Friday, June 27th.

Evaxion A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.